	US 12,268,632 B2
	Self-retaining implantable drug delivery device
Merrill Goldenberg, Newbury Park, CA (US); and Steven H. Rauchman, Mission Hills, CA (US)
Assigned to GoldenBiotech, LLC, Newbury Park, CA (US)
Filed by GoldenBiotech, LLC, Newbury Park, CA (US)
Filed on May 13, 2019, as Appl. No. 16/411,111.
Claims priority of provisional application 62/714,383, filed on Aug. 3, 2018.
Claims priority of provisional application 62/670,766, filed on May 12, 2018.
Prior Publication US 2020/0268554 A1, Aug. 27, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. A61F 9/00 (2006.01); A61F 2/16 (2006.01); A61F 9/007 (2006.01); A61K 9/00 (2006.01); A61K 47/34 (2017.01)

CPC A61F 9/0017 (2013.01) [A61F 2/16 (2013.01); A61F 9/00781 (2013.01); A61K 9/0087 (2013.01); A61K 47/34 (2013.01); A61F 2250/0067 (2013.01)]

19 Claims

1. A controlled-release drug depot comprising:

a) a polymer matrix comprising a silicone polymer matrix material and a prostaglandin analogue, wherein the prostaglandin analogue is present in an amount of from 1% to 25% of the total weight of the polymer matrix material;

b) from one to five coating layers on an outer surface of the polymer matrix that form a drug impermeable membrane, the one to five coating layers having at least one coating layer comprising a poly(p-xylylene) polymer or a metallic material; and

c) from one to five depot channels, wherein each of the one to five depot channels being a tunnel that entirely traversing thorough the polymer matrix and the one to five coating layers, and each of the one to five depot channels providing a controlled release of the prostaglandin analogue; and

wherein the controlled-release drug depot is a sustained-release formulation that releases the prostaglandin analogue over a period of from 7 days to 90 days.